TaiMed Biologics Inc. (TPEX:4147)
Taiwan
· Delayed Price · Currency is TWD 49.40
+1.35 (2.81%)
Apr 29, 2026, 1:30 PM CST
TaiMed Biologics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -167.78 | -201.83 | -194.81 | -269.29 | -470.93 | Upgrade
|
| Depreciation & Amortization | 150.47 | 150.1 | 150.67 | 151.73 | 152.13 | Upgrade
|
| Other Amortization | 3.14 | 4.18 | 4.72 | 4.72 | 4.53 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.61 | 2.32 | - | - | 24.18 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.69 | - | 29.05 | 122.81 | -26.76 | Upgrade
|
| Stock-Based Compensation | 8.77 | 25.36 | 10.51 | 12.27 | 10.22 | Upgrade
|
| Other Operating Activities | 80.68 | 80.78 | 5.82 | 168.85 | 101.38 | Upgrade
|
| Change in Accounts Receivable | 23.95 | 57.47 | -62.24 | 59.54 | 97.94 | Upgrade
|
| Change in Inventory | 89.44 | 185.47 | 110.85 | -382.84 | 14.84 | Upgrade
|
| Change in Accounts Payable | 80.25 | -12.74 | 13.41 | -122.49 | 116.79 | Upgrade
|
| Change in Unearned Revenue | -79.01 | -113.31 | -27.93 | -339.16 | 113.91 | Upgrade
|
| Change in Other Net Operating Assets | -1.06 | -557.36 | -65.64 | -11.33 | -349.5 | Upgrade
|
| Operating Cash Flow | 191.14 | -379.55 | -25.6 | -605.21 | -211.28 | Upgrade
|
| Capital Expenditures | -22.67 | -8.06 | -6.15 | -3.56 | -9.69 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | - | 0.41 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.1 | -11.3 | - | -1.21 | -3.87 | Upgrade
|
| Investment in Securities | 176.7 | -695.39 | -12.88 | 110.88 | 204.07 | Upgrade
|
| Other Investing Activities | 0.09 | -0.1 | 2.58 | - | - | Upgrade
|
| Investing Cash Flow | 154.02 | -714.84 | -16.46 | 106.12 | 190.92 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 200 | - | Upgrade
|
| Total Debt Issued | - | - | - | 200 | - | Upgrade
|
| Short-Term Debt Repaid | - | -200 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -29.5 | -28.98 | -16.05 | -1.98 | -1.93 | Upgrade
|
| Total Debt Repaid | -29.5 | -228.98 | -16.05 | -1.98 | -1.93 | Upgrade
|
| Net Debt Issued (Repaid) | -29.5 | -228.98 | -16.05 | 198.02 | -1.93 | Upgrade
|
| Issuance of Common Stock | 8.78 | 1,645 | 35.28 | 10.31 | 4.71 | Upgrade
|
| Other Financing Activities | -0.92 | -4.27 | - | 0.05 | 0.01 | Upgrade
|
| Financing Cash Flow | -21.64 | 1,412 | 19.23 | 208.38 | 2.79 | Upgrade
|
| Foreign Exchange Rate Adjustments | -5.37 | 11.54 | -0.28 | 13.21 | -2.9 | Upgrade
|
| Net Cash Flow | 318.15 | 329.22 | -23.1 | -277.51 | -20.47 | Upgrade
|
| Free Cash Flow | 168.48 | -387.61 | -31.75 | -608.77 | -220.96 | Upgrade
|
| Free Cash Flow Margin | 27.56% | -63.52% | -6.46% | -108.13% | -53.44% | Upgrade
|
| Free Cash Flow Per Share | 0.62 | -1.45 | -0.13 | -2.41 | -0.88 | Upgrade
|
| Cash Interest Paid | 10.74 | 12.71 | 14.76 | 9.88 | 7.44 | Upgrade
|
| Levered Free Cash Flow | 316.45 | -268.47 | 82.39 | -217.42 | -191.55 | Upgrade
|
| Unlevered Free Cash Flow | 323.14 | -260.59 | 91.65 | -211.11 | -186.9 | Upgrade
|
| Change in Working Capital | 113.57 | -440.47 | -31.56 | -796.29 | -6.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.